Results 31 to 40 of about 25,099 (263)

Inhibitory effect of benzimidazole derivatives on cholinesterases of animals in the presence of different substrates [PDF]

The Ukrainian Biochemical Journal, 2014
Specifically synthesized group of benzimid­azole derivatives possessing varying degrees of delocalization of the positive charge in the cation group of the molecule has been studied in order to search for potential cholinergically active compounds and to
N. E. Basova, B. N. Kormilitsyn, A. Yu. Perchenok,, E. V. Rozengart, V. S. Saakov, A. A. Suvorov   +5 more
doaj   +1 more source

Trends and disparities in the use of cholinesterase inhibitors to treat Alzheimer’s disease dispensed by the Brazilian public health system – 2008 to 2014: a nation-wide analysis

Arquivos de Neuro-Psiquiatria
In light of the high cost of dementia treatment, there is legislation authorizing free distribution of cholinesterase inhibitors to those suffering from Alzheimer’s disease in Brazil.
Flávia Silva de Moraes, Mariana Lima Cerqueira de Souza, Giancarlo Lucchetti, Alessandra Lamas Granero Lucchetti   +3 more
doaj   +1 more source

Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement

Biomolecules, 2019
Alzheimer’s disease, a major and increasing global health challenge, is an irreversible, progressive form of dementia, associated with an ongoing decline of brain functioning.
Gabriela Dumitrita Stanciu, Andrei Luca, Razvan Nicolae Rusu, Veronica Bild, Sorin Ioan Beschea Chiriac, Carmen Solcan, Walther Bild, Daniela Carmen Ababei   +7 more
doaj   +1 more source

CHOLINESTERASE INHIBITORS: A LITERATURE REVIEW OF MEDICATION EFFICACY AND SAFETY FOR ALZHEIMER'S DISEASE

, 2021
Background: With a steady increase of seniors in Canada’s overall population, geriatric-associated illnesses such as Alzheimer’s disease (AD) will continue to rise. AD is a progressive neurodegenerative disorder that causes plaque build-up in the brain
Wicklund, Ashley
core  

Cholinesterase inhibitors in advanced dementia with Lewy bodies: increase or stop?

, 2006
INTRODUCTION There is little data on stopping cholinesterase inhibitors in Dementia with Lewy bodies (DLB). Equally, it is not known if increasing the dose of cholinesterase inhibitors may help neuropsychiatric symptoms in advanced DLB.
Pakrasi, Sanjeet, Thomas, Alan, Cousins, David A., McKeith, Ian G., Burn, David J., O'Brien, John T., Lett, Debbie, Mosimann, Urs P.   +7 more
core   +1 more source

Position Statement on Anti-Dementia Medication for Alzheimer’s Disease by Swiss Stakeholders

Clinical and Translational Neuroscience, 2021
The present document represents the position of Swiss health-care associations, clinical and research centers, research-supporting foundations, and the association Alzheimer Switzerland regarding the care of persons with dementia and Alzheimer’s disease.
Giovanni B Frisoni, Jean-Marie Annoni, Stefanie Becker, Tim Brockmann, Markus Buerge, Jean-François Démonet, Dan Georgescu, Anton Gietl, Ulrich Hemmeter, Stefan Klöppel, Thomas Leyhe, Andreas U Monsch, Franco Rogantini, Delphine Roulet Schwab, Egemen Savaskan, Karl Schaller, Armin von Gunten, Gabriel Gold   +17 more
doaj   +1 more source

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies

, 2004
This article reviews the cholinergic changes in Parkinson's disease and dementia (PDD) and dementia with Lewy bodies (DLB), their potential clinical implications, and the available evidence for cholinesterase inhibitors in the treatment of PDD and DLB ...
Aarsland, Dag, McKeith, Ian G., Mosimann, Urs P.   +2 more
core   +1 more source

Brain and Liver Dual‐Targeting Oridonin Nanoparticles to Enhance Aβ Clearance for Alzheimer's Disease Therapy

Advanced Science, EarlyView.
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong, Wenting Hui, Sai Qiao, Qifeng Ji, Miao Liu, Bangle Zhang, Daozhou Liu, Yumei Wu, Siyuan Zhou   +8 more
wiley   +1 more source

Co‐design–related approaches in medication safety for people with dementia: A scoping review

British Journal of Clinical Pharmacology, EarlyView.
Background People with dementia manage complex medication regimens and face a heightened risk of medication‐related harm. Co‐design approaches are increasingly being used to develop interventions/tools to improve medication safety in this population. Objectives To describe how co‐design has been applied in developing interventions or tools related to ...
Zena El‐kadomi, Danijela Gnjidic, Nicole E. Werner, Mouna J. Sawan   +3 more
wiley   +1 more source

Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.

PLoS ONE, 2014
Patients with Alzheimer's disease after an initial response to cholinesterase inhibitors may complain a later lack of efficacy. This, in association with incident neuropsychiatric symptoms, may worsen patient quality of life.
Gianfranco Spalletta, Carlo Caltagirone, Alessandro Padovani, Sandro Sorbi, Mahmood Attar, Delia Colombo, Luca Cravello, E V O L U T I O N study Working Group   +7 more
doaj   +1 more source